Our focus is on neurochemicals acting on the peripheral and central nervous system

We are enthusiastic about neurochemicals acting as agonists or antagonists on G-protein coupled receptors located in the peripheral and central nervous system. Our goal is to address the clinical needs to diagnose and treat the neurological pathologies at the origin of the disease; thus, avoiding a merely systematic treatment and rather stopping or delaying disease progression.

The chemical structure of small molecules is the key for successful drug design and development for both imaging probes and therapeutics. The combined, interdisciplinary knowledge of medicinal chemists, pharmacists and physicians allows drug adjustment and pave the way towards the application of our substances as tools for image-guided therapy.

The bottleneck of the drug development process is the preclinical screening of a compound library, as we still lack substantial methods for a fast and reliable biological assessment. We developed a complex dynamic 3D-cell culture method, which mimics the tissue situation and has the potential to fasten the screening process. Moreover, it conforms with the 3Rs (reduce, replace, refine) rule in animal ethics and will contribute to reduce the number of animals needed in drug testing.

Our main interests lie in

  • Inventive drug and tracer development of neurochemicals
  • Innovative drug screening methods
  • Interdisciplinary approaches close to medical application

EANM 2021 Plenary Lecture - Isotopes Past and Future

Missed the EANM 2021 plenary lecture on the availability of medicinal radioisotopes.

You can still watch it here.

CBmeds microONE promo video

For the SDG-3 presentation at the austrian parlament, our consortium of the FFG funded microONE project (CBmed, Univie, MUW, among others) produced a nice promo-video. Thank you to Thomas Wadsak for the nice production. (German only)

News and announcements


We were honoured to present our FFG funded microONE Project on the effects on micro- and nanoplastic on human health during the SDG3 presentations (Sustainable Development Goals) in the austrian parlialment.


Foto© Parlamentsdirektion/Johannes Zinner


In a continous effort to bring woman in science at the forefront, I want to thank NucMedBiol for the Special Issue on Woman in radiopharmaceutical/radiochemical science. Radiochemistry and Nuclear Medicine was always a discipline driven by woman. It is an enormous honor to be listed here.


The article on "Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET" was highlighted by JNM. Congratulation to Andreas Buck and our industry cooperation partners von PentixaPharm.


As a joint collaboration, Prof. Vida Malinauskiene from Kaunas Institute of Technology visited our Departement and held an enthusiastic workshop on green chemistry.


Dorka finished her Master degree with defending her master thesis with the title „Estimation of competitive antagonist affinity of mAChR ligands from functional inhibition curves using Cheng-Prusoff equation“. Congratulations


Congratulation Jonas Kilian

We congratulate Jonas Kilian for defending his PhD-thesis with the title "Design, synthesis, and biological evaluation of novel ligands for teh muscarinic acetylcholine receptor M1 towards their potential application as diagnostic probes".